* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced
Dish of the day
Admissions:
Delistings:
What’s baking in the oven? **
Potential**** Initial Public Offerings:
7th May: Time To ACT plc, an engineering business focused on technology for the energy transition sector, has announced its intention to seek Admission to trading on the Aquis Stock Exchange Growth Market. The Company reports it is revenue generating, profitable in FY23, with £1.9m cash in the bank at 31st March 2024. The Company's application to the AQSE Growth Market is not conditional on it raising funds. However, the Company is seeking to raise up to £1m of new money to de-risk growth and in support of its strategy of coupling organic growth and acquisition.
Reverse Takeovers:
13th May: Amur Minerals Corporation announced that the Company has executed a sale and purchase agreement to conditionally acquire the entire issued and to be issued share capital of Extruded Pharmaceuticals, a UK-based drug delivery technology company focused on the local delivery of chemotherapy drugs, for an aggregate consideration of £5.5m. The reverse takeover is awaiting the approval of Shareholders at a General Meeting on 29 May.
Change of Market:
Dual Listing:
Banquet Buffet***
Angling Direct 36.5p £28.2m (ANG.L)
The fishing tackle and equipment retailer announces its financial results for the twelve months ended 31 January 2024. Revenue increased 10.2% to £81.7m (2023: £74.1m), profit before tax increased 126.8% to £1.5m (2023: £0.7m) and the net cash position increased to £15.8m (2023: £14.1m). The Company saw resilient Q1 trading against an uncertain consumer landscape and sub-optimal weather conditions, but still total Q1 FY25 sales increased 4.0%, achieving growth in the UK and Europe.
Celadon Pharmaceuticals 105p £57.9m (CEL.L)
The pharmaceutical Company focused on the development, production and sale of breakthrough cannabis-based medicines announces its audited final results for the year ended 31 December 2023. Revenue increased to £75k (2022: £24k), the loss before tax decreased to £7.52m (2022: £18.12m) and the cash balance decreased to £1.26m (2022: £5.06m). While the UK market for cannabis-based medicines is still in its infancy, there are signs that it is beginning to mature. The Company remains confident of the medium to long-term sector outlook and the prospects for Celadon within this market.
EnSilica 57p £48.5m (ENSI.L)
The chip maker of mixed signal Application Specific Integrated Circuits announces a pre-close trading update for the year ended 31 May 2024. The Board expects to report record revenues of approximately £25m (2023 £20.5m) and profit after tax of approximately £1.9m (2023: £1.8m). At the end of April cash balances were £1.3m and net debt was £2.1m. During FY 24 £0.9m of debt will have been repaid in line with debt repayment schedules. Looking ahead to FY25, the Board is confident that the Company will continue to improve on its opportunities to capitalise on the significant growth opportunity that exists within the communications, industrial, automotive and healthcare sector.
Gateley (Holdings) 115.5p £152.0m (GTLY.L)
The professional services group announces a trading update ahead of its full year results for the year ended 30 April 2024. Revenue is expected to grow 5.7% to £172m (2023: £162.7m) and profit before tax is expected to be £22.8m (2023: £25.1m). The group maintains a strong balance sheet with net cash of £3.3m (2023: £4.3m), net of in-Period investment in acquired and organic opportunities to generate future growth and supporting the employee benefit trust with its recent purchase of shares.
Newmark Security 102.5p £9.6m (NWT.L)
The provider of electronic, software and physical security systems announces an update on trading for the year ended 30 April 2024. The group expects to report robust year-on-year revenue growth with revenues of not less than £22m (2023: £20.3m) and a cash position of £1.1m (2023: £0.6m). The combination of increased cross-selling to existing customers and new blue-chip customer wins contributed to the strong second half.
OPG Power Ventures 11.6p £46.6m (OPG.L)
The developer and operator of power generation plants in India announces a trading update in respect of the full year ended 31 March 2024. Subject to audit, the Company expects to report FY24 revenues, EBITDA of no less than £160m and £16m respectively and net debt of approximately £12m (2023: £16.1m). During FY24, with profitable revenue generation and continued deleveraging, the Company has significantly strengthened its balance sheet and liquidity position which provides OPG with the financial strength and latitude to pursue new growth opportunities in energy transition.
Pennant International Group 27p £10.0m (PEN.L)
The systems support and training solutions Company announces the following update. Trading in the year to date has been in line with the Board's expectations although the Group has incurred exceptional, non-recurring costs of circa £0.3m in relation to aborted corporate activity. Management's assessment is that the Group's key markets are starting to see a significant increase in activity, and in response to customer tenders and requests for proposals, the Group has quoted on over £32m of new business opportunities during the last six months.
Prospex Energy 5.7p £18.8m (PXEN.L)
The Company that invests in energy projects with a focus on Europe announces its audited Final Results for the year ended 31 December 2023. The Company recorded a loss for the year of £1.23m (2022: profit: £7.14m ). This was caused by the re-adjustment of commodity prices to more normal levels, following the unsustainable and inflated high prices of 2022 attributable to the commencement of the Russian-Ukraine conflict. Revaluation of investments at fair value lead to a reduction of 2.9% to £15.59m (2022: £16.06m) and the unrealised loss of £469k (2022: gain £9.37m). The Company is now debt-free, self-sustaining on a business-as-usual basis, and in a much stronger financial position than it was at the end of the prior year.
Various Eateries 21.5p £37.6m (VARE.L)
The owner, developer and operator of restaurant, clubhouse and hotel sites in the UK announces an update on trading for the 26-week period ending 31 March 2024. Revenue in the period grew 10.2% to £22.7m (H1 2023: £20.6m) and cash was £7.2m (H1 2023: £3.1m). Trading at the start of the second half has been resilient, despite the uncharacteristically wet weather, and management is optimistic ahead of the important summer trading months.
Zytronic 52.5p £5.3m (ZYT.L)
The manufacturer of touch sensors announces its consolidated interim results for the six months ended 31 March 2024. Revenue decreased to £3.3m (2023: £4.7m), the loss before tax decreased to £0.6m (2023: £0.9m) and the net cash position decreased to £3.7m (2023: £4.7m). A core objective remains the return to positive cash generation and growth over the medium term. While it is too early to call this the start of a sequence of recovering quarters, it does give some grounds for optimism while the Company undertakes a formal business and operational review process.
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.